AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05267925 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CuraLin
Description: CuraLin™ is a dietary supplement manufactured by NutraStar Inc. and sold by CuraLife; it is a blend of nine ayurvedic plants and herbs.~The CuraLin formulation contains the following ingredients (per 2 capsules):~* Mormordica charantia (fruit) - 300mg~* Gymnema sylvestre (leaf) - 80mg~* Trigonella foenum-Graecum (seed) - 100mg~* Curcuma longa (rhizome) - 100mg~* Phyllanthus embilica officinalis (fruit) - 100mg~* Swertia chiraytia (leaf) - 80mg~* Syzgium Cumini (seed) - 100mg~* Neopicrorhiza Picrorhiza/Scrophulariiflora Kurroa (root) - 100mg~* Cinnamoum verum/zeylanicum - 40 mg~* Hydroxypropyl methylcellulose~* Rice Flour
Study NCT04938219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gloves filled with warm tap water
Description: The intervention in the treatment group will consist of nonsterile gloves, filled with regular tap water at a comfortable warm temperature and sealed with a plastic clip. The temperature of the water will not be measured, the investigators will take a temperature that feels comfortable in their hands
Study NCT06486649 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multimodal Large Language Model Diagnosis
Description: Diagnosis for heart failure with preserved ejection fraction (HFpEF) using the multimodal large language model MedGuide-72B.
Study NCT06486649 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Routine diagnostic and therapeutic procedure
Description: Routine diagnostic and therapeutic procedure
Study NCT05408923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline 0.9%
Description: Control group will get normal saline for irrigation throughout the case.
Study NCT05408923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (0.05% chlorhexidine gluconate (CHG) in sterile water)
Description: Intervention group will get Irrisept irrigation (0.05% CHG in sterile water) throughout the case.
Study NCT05625919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus for Injection (Albumin Bound)
Description: Sirolimus for injection (Albumin-bound), intravenously, once a week, 21 days per cycle (two weeks-on and one week-off)
Study NCT05222425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xagrotin
Description: A herbal compound
Study NCT04669964 — intervention group
Intervention type: PROCEDURE
Intervention: Intravenous Hydration
Description: Patients will receive daily intravenous hydration of normal saline based on their ileostomy output.
Study NCT06003907 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional
Description: hot application electrotherapy ultrasound mobilization joint range of motion exercises stretching exercises balance exercises posture exercises
Study NCT06003907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional
Description: hot application electrotherapy ultrasound mobilization joint range of motion exercises stretching exercises balance exercises posture exercises
Study NCT06003907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional and complementary medicine methods
Description: The Graston Technique is a form of manual therapy known as instrument assisted soft tissue mobilization. Graston massage is performed using titanium-coated metal rods specially designed for different parts of the body.~Cupping therapy is a treatment method that creates a regional vacuum to increase the blood circulation of the person and provide healing.
Study NCT06234696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: entrepreneurial intervention
Description: The experimental group will be given psychoeducation for 4 weeks.
Study NCT06618703 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Blood sample, urine sample, osteodensitometry
Description: Blood sample, urine sample, osteodensitometry
Study NCT06459570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality based exercises
Description: one experimental group with Virtual reality-based exercises. Subjects in the VR-based exercises will receive 12 sessions of the VR-based exercises treatment, administered four times a week over 3 weeks, with each session lasting approximately 60 minutes.
Study NCT06459570 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard physical therapy
Description: Second control group with standard physical therapy and occupational therapy treatment.Subjects in the control group will receive 12 sessions of physical therapy treatment involving passive and active range of motion exercises, muscle strengthening, and therapeutic stretching, administered four times a week over a span of 3 weeks, with each session lasting approximately 60 minutes.
Study NCT05685862 — intervention group
Intervention type: DEVICE
Intervention: Laser Speckle Contrast Imaging using the PerfusiX-Imaging device
Description: Patient will undergo the standard-of-care gastric conduit procedure and in addition, peroperative Laser Speckle Contrast Imaging of the gastric conduit and eosophagus will be performed.
Study NCT04988477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic care management
Description: Quarterly brief provider intervention (the 5As) and 3 quarterly outreach calls over 3 months.
Study NCT05366309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored education
Description: Tailored Education: A delegated investigator will review the SD memory card data and share the results with the participant and/or parent/guardian. The investigator will explain whether there are partial or critical errors to inhalation technique that have been recorded. The participant will be informed about their overall adherence; including how and when they used their asthma medications. If errors in medication use are identified, specific coaching will be provided to help eliminate errors.
Study NCT05366309 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care education
Description: Participants randomised to this group will receive usual care in terms of their education.
Study NCT05448287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health and family planning
Description: Promotion of health and family planning behaviors
Study NCT05448287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Promotion of maternal, infant, and young child feeding behaviors and nutrition
Study NCT05448287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Agriculture and homestead food production
Description: Promotion of knowledge and practices about homestead food production
Study NCT05448287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water, sanitation, and hygiene
Description: Promotion of behaviors to improve water, sanitation, and hygiene
Study NCT05222425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Green tea
Description: Normal green tea
Study NCT05317546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: In counterbalanced order, 50 youth (ages 16-22) will receive 600mg of cannabidiol or placebo three hours before a neuroimaging and behavioral assessment paradigm, separated by an approximate 18-day washout period.
Study NCT05389527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab+Lenvatinib
Description: After enrollment, subjects receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for 9 weeks: Lenvatinib 8 mg (body weight \<60 kg) or 12 mg (body weight ≥60 kg) orally once daily for 9 weeks.~Subjects conduct surgery 1 week after the last dose of Lenvatinib. 4 weeks after surgery, Pembrolizumab and Lenvatinib will restart as adjuvant treatment for up to 1 year.
Study NCT06144268 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZyMōt Multi (850µL)
Description: An amount of 850 µl untreated semen sample will be loaded into the inlet chamber with a help of a sterile insulin-type syringe. A volume of 750 µl of Sage Quinn's AdvantageTM Medium with Hepes + 5% HSA-solution medium will be placed on top of the membrane (outlet chamber). After 30 min of incubation in a humidified incubator (37°C), 500 µl of medium, containing the selected spermatozoa, will be retrieved from the upper side of the membrane (retrieval chamber). An amount of 400 µl will be necessary for the IUI procedure.
Study NCT06144268 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Density Gradient Centrifugation
Description: The gradient columns will be prepared by placing 1 ml 80% gradient media in a centrifuge tube and an additional 1 ml of 40% gradient layered on top.~The raw semen sample will be placed on top of the gradient (1ml semen/gradient tube) and centrifuged at 300xg for 20 minutes. The sperm pellet will be collected and washed 2 times for 5 min at 800xg in Sage Quinn's AdvantageTM Medium with Hepes + 5% HSA-solution.~The resulted pellet will be resuspended in the washing solution in a volume that will provide at least 1x106 forward motile spermatozoa in 400 µl, as this amount is necessary for IUI procedure.
Study NCT05183737 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Microcapsules with turmeric and propolis
Description: Participants will receive microcapsules containing 0.250 milligrams of turmeric 95% curcumin and 0.250 milligrams of green propolis, twice a day for 12 weeks
Study NCT05183737 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Microcapsules with turmeric and propolis
Description: Participants will receive microcapsules containing 0.250 milligrams of turmeric 95% curcumin and 0.250 milligrams of green propolis, twice a day for 12 weeks
Study NCT05814536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-218 capsule
Description: Take AB-218 orally twice daily, ideally with 12 hours between doses (and a minimum of 8 hours between doses), at a dose assigned by the study. The study treatment is defined as occurring in 28-day cycles with continuous dosing. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs earlier.
Study NCT05573490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Participants will be asked to complete approximately 45 minutes of training, 4-5 sessions per week for 14 weeks (corresponding to approximately 40 hours of training total). Training will be completed via BrainHQ, a mobile application that, as used in this study, meets the FDA's definition of a medical device.
Study NCT05573490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi- Qi Gong
Description: Participants will be asked to complete 14 hours of training total (in 30-minute sessions, 2 days per week for 14 weeks).
Study NCT05573490 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brain Games
Description: Participants will be asked to complete 40 hours of training total (in 45-minute sessions, 4 to 5 days per week for 14 weeks). Training will be completed via BrainHQ, a mobile application that, as used in this study, meets the FDA's definition of a medical device.
Study NCT05573490 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Participants will be asked to engage in stretching exercises twice per week, for approximately 15 minutes per session. This will total of approximately 7 hours over the course of 14 weeks.
Study NCT05418894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Directional Deep Brain Stimulation
Description: Boston Scientific Vercise DBS leads and 16-channel implanted pulse generators (IPGs) will be implanted to control the shape and size of stimulation
Study NCT05425043 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocytes
Description: Receive granulocytes for 7 consecutive days after engraftment post transplant
Study NCT05373992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screen Time Restriction (ST-Restricted)
Description: Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) for the first 72-hours following the initial clinic visit. Following the first 72-hours of restricted screen-time, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
Study NCT05373992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Description: Engage in 30-minutes of aerobic exercise daily for the first 72-hours following the initial clinic visit in the form of a stationary exercise bike, treadmill, or outdoors. The exercise intensity will be prescribed not to exceed 60% of the age-based maximum heart rate (HR). Following the first 72-hours of prescribed AE, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
Study NCT05373992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screen-time restricted plus aerobic exercise (STR+AE)
Description: Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) while concurrently engaging in daily aerobic exercise in the form of a stationary exercise bike, treadmill, or outdoors, for the first 72-hours following the initial clinic visit. The exercise intensity will be prescribed not to exceed 60% of the age-based maximum heart rate (HR). Following the first 72-hours of prescribed STR+AE, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
Study NCT05373992 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Only
Description: Participants will be instructed to follow a prescribed stretching program for the first 72-hours following the initial clinic visit. Following the first 72-hours of prescribed stretching, participants will follow the standard of care until the second clinic visit at 7-days post the first clinic visit. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
Study NCT05930834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: All subjects will undergo exercise training for 4 wks. 45-60 min of exercise, 4 sessions/wk supervised, 1 session unsupervised. intensity 60% of VO2 max
Study NCT05160038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embodied virtual reality
Description: An immersive headmounted display visually depicts a relaxing woods scene, coupled with a virtual avatar that either shows bodily illusions or no bodily illusions
Study NCT06199947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsies and Blood collection
Description: Each participant will have 2 additionnal biopsies during his/her diagnostic endoscopy plus two blood test during his/her inclusion
Study NCT06392685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Silane coupling agent
Description: Silane coupling agent (Porcelain primer) will be applied following the acid etch rinsing and drying step, for 30 seconds and then it will be thoroughly dried using air syringe then universal adhesive with regular silane will be actively applied for 20 seconds and then it will be light cured for 20 seconds and final restoration will be done
Study NCT06392685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adhesive containing silane.(Intervention 1 )
Description: Universal adhesive with regular silane will be applied for 20 seconds, air thinned for 10 seconds and then it will be light cured for 20 seconds and final restoration will be done using same resin composite material
Study NCT06392685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acid resistance silane containing adhesive.(Intervention 2)
Description: Acid resistance silane containing adhesive will be applied for 20 seconds, dry with gentle air for 3 seconds, then with stronger air and light cured for 10 seconds and final restoration will be done
Study NCT05716841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ballistic exercises
Description: stretching and then strengthening of the upper limb through ballistic six exercises from a moderate to intense manner with 3 sets of 10 repetitions with a 30sec gap between sets, 3 Sets of 15 repetitions with a 30sec gap between sets, and 3 sets of 20 repetitions with a 30sec gap between sets for 3 to 4 days per week for six weeks.
Study NCT06353659 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast-enhanced Ultrasound
Description: Patients with acute kidney injury high risk factors (KDIGO 2012) will undergo a contrast-enhanced ultrasound within 24 hours of admission to the ICU
Study NCT05042713 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WaveOne Gold, One Curve, OneFlare
Description: During the endodontic treatment of molar teeth diagnosed with irreversible pulpitis, the effect on postoperative pain when single file systems with rotational (OneCurve) and reciprocal (WaveOne Gold) kinematics are used with and without coronal flaring instrument (OneFlare) will be compared.
Study NCT06643052 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05250687 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR- High intensity focused ultrasound
Description: The intervention treatment is MR-HIFU, which will be given as a standalone treatment. MRHIFU treatment will be delivered using the ExAblate 2100 System (INSIGHTEC, Tirat Carmel, Israel), which is an FDA-approved device for pain palliation of bone metastasesThe ExAblate focused ultrasound device operates in conjunction with an MRI machine. Gadavist is being administered intraveneously as contrast medium for MRI.
Study NCT05250687 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiotherapy
Description: Standard of care for pain palliation of bone metastases consists of single fraction external beam radiotherapy of 8-16 Gray (Gy) or a multi-fraction regime of 20 Gy in 5 fractions, 24 Gy in 6 fractions or 30 Gy in 10 fractions. The radiation schedule is at the discretion of the treating radiation oncologist.
Study NCT05326308 — intervention group
Intervention type: DRUG
Intervention: Zanubrutinib
Description: according to the Summary of Product Characteristics (SmPC).
Study NCT05326308 — intervention group
Intervention type: DRUG
Intervention: Obinutuzumab
Description: according to the Summary of Product Characteristics (SmPC).
Study NCT06332950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab, Irinotecan Liposome (II)
Description: Adebrelimab:1200 mg, IV, D1, Q3W~Irinotecan Liposome (II): RP2D, IV, D1, Q3W~Escalating doses to determine recommended phase 2 dose (RP2D) of Irinotecan Liposome (II).~Participants will receive Adebrelimab (1200 mg, IV, D1, Q3W) plus the RP2D of Irinotecan Liposome (II).
Study NCT06332950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab, Irinotecan Liposome (II), Famitinib
Description: Adebrelimab:1200 mg, IV, D1, Q3W~Irinotecan Liposome (II): RP2D, IV, D1, Q3W~Famitinib: RP2D, QO, QD~Escalating doses to determine recommended phase 2 dose (RP2D) of Famitinib.~Participants will receive Adebrelimab (1200 mg, IV, D1, Q3W) plus the RP2D of Irinotecan Liposome (II) and Famitinib.
Study NCT04921514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SASRQ questionnaire
Description: During an interview with a trained psychologist, the presence of acute stress will be assessed by the SASRQ test within one week of the occurrence of a sudden recovered death.~The diagnosis of acute post-traumatic stress disorder is made according to the presence of at least three dissociative symptoms out of five, and other symptoms of re-experiencing, avoidance or marked anxiety or hypervigilance. Each symptom is thus evaluated dichotomously. A symptom is present if the intensity of the response is 3 or more (0 from 0 to 2 and 1 from 3 to 5).
Study NCT04921514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCL-5 with LEC-5 questionnaire
Description: This questionnaire will be completed during an interview with a psychologist trained in the protocol, 3 months after the sudden death.~The PCL-5 is a 20-item self-report questionnaire that assesses the 20 symptoms of PTSD according to the DSM-V. It is associated with the LEC-5 questionnaire.~The self-reported scale uses ratings of 0 to 4 to assess each of the symptoms.~A threshold of 38 on the PCL-5 seems reasonable to suggest the presence of PTSD.
Study NCT05200936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-120
Description: MM-120 is a psychedelic drug that can cause intensified thoughts, emotions, and sensory perception. At sufficiently high dosages MM-120 manifests primarily visual, as well as auditory, hallucinations.
Study NCT05200936 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A treatment which is designed to have no therapeutic value.
Study NCT04804813 — intervention group
Intervention type: DRUG
Intervention: Cabozantinib
Description: Cabozantinib tablets
Study NCT05559437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levo-bupivacaine 0.25
Description: The blockade of ilioinguinal/iliohypogastric nerves in the anterior abdominal wall has improved postoperative analgesia after open inguinal hernia repair. Other new blocks needs to be investigated
Study NCT05116020 — intervention group
Intervention type: OTHER
Intervention: Usual chiropractic care
Description: Usual chiropractic care in Switzerland can include spinal manual therapy, soft-tissue therapy, use of electric therapeutic modalities (low level laser therapy, therapeutic ultrasound, interferential current), acupuncture, prescription medication, exercise, education and reassurance.
Study NCT06043479 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fever Management Education
Description: The mothers were provided with a three-day training consisting of six sessions. Two sessions were held each day, with each session lasting for 30 minutes.